The 9th DIA China Annual Meeting

On May 21-24, 2017, the DIA China Annual Meeting will bring together global pharmaceutical professionals to discuss critical topics and themes surrounding the regulation, discovery, development, and life cycle management of health care products. The theme of this meeting, “Drug Innovation Driven by Unmet Medical Needs,” will attract more than 2000 pharmaceutical R&D professionals from different continents and regions, involved at all levels of the health care product development spectrum. Please join us to discuss recent and upcoming transformational changes for China’s innovation and regulatory environments.

This year will also debut our special DIAmond Sessions, which will introduce global views into our perspective of the Chinese pharmaceutical eco-environment. Sessions will model the experience from the global DIA 2016 Annual Meeting in the US. As the largest multidisciplinary event in DIA Asia, other highlights will include 100+ exhibit booths and a new, unique hub for R&D and emerging companies to showcase themselves in “Innovation Row.”

Come and join our neutral, global platform to exchange knowledge, advance change, and cross collaborate towards patient-centric biopharmaceutical innovation.

Ning XU, MD, MBA

Executive Vice President, Head of Clinical Development and Regulatory Affairs, Zai Lab

Bin XUE

Director-General, China Center for Food and Drug International Exchange, China Food and Drug Administration

Bei HU, PhD, Prof.

Director, Clinical Pharmacological Research Center, Peking Union Medical College Hospital

Janet LV

Head of Regulatory, Asia Pacific, Roche (China) Ltd.

Ying SHAO, PhD

Vice President and Director of R&D Center, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Ling SU, PhD

Professor and Director, Institute of Drug Regulatory Science, Shenyang Pharmaceutical University

Venture Partner, Lilly Asia Ventures

JingSong WANG, MD, PhD

Advisor to Atlas Venture

Ning XU, MD, MBA

Executive Vice President, Head of Clinical Development and Regulatory Affairs, Zai Lab

Co-Chairs, 9^th DIA China Annual Meeting

Bin XUE

Director-General, China Center for Food and Drug International Exchange, China Food and Drug Administration

Co-Chairs, 9^th DIA China Annual Meeting

Carol ZHU, MBA

Senior Vice President and Managing Director, DIA Greater China

Lili CAO, Director, Division of External Cooperation, CCFDIE, CFDA

Xiaochun CAO, MPS, Executive Vice President & Board Secretary, Tigermed Consulting Ltd.

Tony GUO, PhD, Director, Biostatistics, MSD R&D (China) Co., Ltd.

Qin HUANG, PhD，Center for Drug Evaluation, CFDA

Min IRWIN, MD, PhD，Vice President, Takeda Development Center Asia Head

Vera LIANG, MD, Senior Director, Disease Area Cluster Leader Generics, Shanghai Site Head, Safety Surveillance and Risk Management, Pfizer China R&D Center

Melly LIN, Senior Regulatory Manager, CMC Policy, Roche (China) Holding Ltd.

George LIU, PhD, Head of Early Development and Scientific Operation, Harbour Biomed

Zhiqiang NING, MD, PhD, Vice President R&D, Shenzhen Chipscreen Biosciences Ltd.

Roger QU, PhD, Head of Clinical Statistics, Pfizer R&D Center

Hualong SUN, MD, PhD, General Manager, Meta Clinical Technology

Jingsong WANG MD, PhD, Advisor to Atlas Venture

Li WANG, MD, PhD, Vice President, Medical, Eli Lily & Company

Wendy YAN, MD, MBA, Senior Vice President, Head of Regulatory/Affairs, BeiGene (Beijing) Co., Ltd.

Steve YANG, PhD, Executive Vice President and Chief Operational Officer, Wuxi Pharma Tech Inc.

Joe ZHANG, MD, PhD Head of Preclinical R&D, Simcere Pharmaceuticals

Dayao ZHAO, MD, PhD, Vice President and Lead, China Drug Development

Pinghui FENG, PhD, Associate Professor with Tenure, Department of Molecular Microbiology and Immunology, University of Southern California

Zhengqing LI, PhD, Global Vice President and General Manager, China R&D Center, MSD

Gefei ZENG, PhD, Head of Strategic Planning and Research Informatics, MSD China R&D

• Regulatory Science
• CFDA Townhall
• Clinical Operations -- Multi-collaborations, A Pathway to High Quality Studies
• Oncology Drug Development
• Quantitative Science in Transformation -- with Evolving Regulatory Landscape and Science, the Opportunity and Challenges for Science of Clinical Data
• Medical Affairs – Focus on Medical Value to Satisfy Unmet Patient Needs
• Biologics & Biosimilar
• Pharmacovigilance & Drug Safety – Patient Safety, A Constant Focus
• Early Stage Drug R&D Strategies and Tactics
• Entrepreneur Forum
• Rare Diseases – Unmet Patient Needs
• Hot Topics & Late Breaker
• Clinical Submission Documents- Embrace New Regulatory Requirements

• Generic Drugs R&D
• Pharmacovigilance and Risk Management from Clinical Trials
• Medical Affairs

To learn more about the conference:
Contact: Runshan CHEN     Email: runshan.chen@DIAglobal.org     Tel: +86 10 57042653

Exhibition: more than 100 booths for nearly 100 companies, with sizes from 2M*2M to 3M*3M etc. for your selection. Only a limited number of booths are available now. First come, first serve until we are fully booked.

Meeting Support Opportunities: DIA provides many meeting support opportunities, including meeting attendee bags, welcome reception, VIP reception, refreshment breaks, as well as other ads opportunities in the Convention Center, such as banner ads, column wraps ads and so on.

Ads on Meeting Publication: full-page ads on inside front cover and inside back cover, half-page ads on inside pages, and double-page spread ads.

China Center for Food and Drug International Exchange (CCFDIE) is responsible for the ads, booth and hosting sales of DIA China Annual Meeting.